Related Experiment Video
Updated: Aug 8, 2026

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Bivalirudin anticoagulation for a patient with hypercoagulable immune syndromes undergoing mitral valve surgery
Rebecca L Cain1, Bruce D Spiess, Mark Nelson
1Department of Anesthesiology, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298-0695, USA. rebeccs13@aol.com
Abstract:
Unfractionated heparin has been a near universal anticoagulant for cardiac surgery; however it is contraindicated in heparin-induced thrombocytopenia type II. Alternative anticoagulants such as bivalirudin (a direct thrombin inhibitor) are being utilized. Bivalirudin was successfully used in an immunologically complex patient (diagnoses of heparin-induced thrombocytopenia type II, systemic lupus erythematosus, antiphospholipid syndrome, and dialysis-dependent renal failure) requiring cardiopulmonary bypass. Thrombotic events are common in antiphospholipid syndrome patients undergoing cardiac surgery utilizing high-dose heparin. This may represent unrecognized heparin-induced thrombocytopenia type II. Our patient did not experience perioperative thrombotic or bleeding complications. The possible cross-reactivity between heparin induced thrombocytopenia type II and antiphospholipid syndrome has not been investigated.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Mitral Stenosis III: Medical Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Mitral Regurgitation III: Medical Management
Mitral Regurgitation IV: Nursing Management
Endocarditis III: Medical Management